Impel-NeuroPharma-Announces-Leadership-Transition-Chairman-Adrian-Adams’-Role-Expanded-To-Chairman-and-CEODownload SEATTLE, May 5, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams, who served as Chairman of the Board of...